#4329
Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)
Introduction:
Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and consist of neuroendocrine tumours G3 (NET G3) and neuroendocrine carcinomas (NEC). They differ in clinical and molecular characteristics, response to treatment and prognosis. Limited prospective data are available on prognostic factors for survival in patients given first-line chemotherapy outside of clinical trials.
Conference:
Presenting Author:
Authors:
Sorbye H,
Hjortland G,
Vestermark L,
Ladekarl M,
Svensson J,
Keywords:
neuroendocrine neoplasm,
neuroendocrine carcinoma,
digestive,
high-grade,
neuroendocrine tumour grade 3,
#4111
Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
Introduction:
Peptide receptor radionuclide therapy (PRRT) presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known.
Conference:
Presenting Author:
Warfvinge C
Authors:
Warfvinge C,
Gustafsson J,
Roth D,
Tennvall J,
Svensson J,
Keywords:
PRRT,
Neuroendocrine tumor,
dose-response,
dosimetry,
#3965
Nordic NEC 2: Characteristics and treatment outcome in a prospective cohort of 698 patients with high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)
Introduction:
Digestive high-grade (HG) neuroendocrine neoplasms (NEN) are rare with limited data on epidemiology, treatment benefit and survival.
Conference:
Presenting Author:
Authors:
Sorbye H,
Hjortland G,
Vestermark L,
Laderkarl M,
Svensson J,
Keywords:
NEC,
NET G3,
digestive,
chemotherapy,
neuroendocrine neoplasms,
#3813
First report of the phase I LuPARP trial assessing 177Lu-DOTATATE in combination with the PARP inhibitor olaparib in patients with somatostatin positive tumors
Introduction:
Patients with metastatic somatostatin receptor positive tumors can be treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. However, all patients do not respond sufficiently, and further treatment optimization is highly warranted. We hypothesize that the tumoricidal effect could be increased by adding a PARP inhibitor which will decrease the ability of the tumor cells to repair DNA-damage, making them more sensitive to radiation and increase the probability of tumor cell death.
Conference:
Presenting Author:
Hallqvist A
Authors:
Hallqvist A,
Sjögren M,
Krantz T,
Holgersson K,
Svensson J,
Keywords:
PRRT,
177Lu-DOTATATE,
olaparib,
